ML
Mary Lynne Hedley, PhD
Board of Directors; Senior Scientific Fellow and Strategic Advisor, The Broad Institute of MIT and Harvard
Centessa PharmaceuticalsTherapeutic Areas
Centessa Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ORX750 | Narcolepsy Type 1 (NT1) | Phase 2 |
| ORX142 | Neurological & Neurodegenerative Disorders | Pre-clinical |
| ORX489 | Neuropsychiatric Disorders | Pre-clinical |
| LockBody Platform Assets | Oncology | Pre-clinical |
Leadership Team at Centessa Pharmaceuticals
MA
Mario Alberto Accardi, PhD
Chief Executive Officer and Director
KA
Karen Anderson
Chief People Officer
TB
Tia Bush
Chief Technology and Quality Officer
JC
John Crowley, CPA
Chief Financial Officer
RD
Raphael Deferiere, CPA
Chief Accounting Officer
IH
Iqbal Hussain
Chief Legal Officer, Chief Compliance Officer and Company Secretary
SK
Stephen Kanes, MD, PhD
Head of R&D and Chief Medical Officer
KM
Kimberly McCormick, PharmD
Senior Vice President, Regulatory Affairs and Medical Writing
KS
Kristen Sheppard, Esq
Senior Vice President, IR and Corporate Communications
CS
Charlene Stoudt
Senior Vice President, Clinical Development Operations